Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Literature DB >> 16870782

Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Abstract

The C-8-methoxy fluoroquinolone moxifloxacin was more lethal against chloramphenicol-treated Mycobacterium tuberculosis than Bay y3114, a C-8-H cognate of moxifloxacin, and two C-8-methoxy fluoroquinolones, gatifloxacin and BMS-433368, which have different C-7 substituents. Thus, an optimal combination of C-7 and C-8 substituents is likely to be important for killing nongrowing M. tuberculosis.

Entities: Chemical Species

Mesh：

Substances：

Year: 2006 PMID： 16870782 PMCID： PMC1538652 DOI： 10.1128/AAC.00250-06

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

18 in total

1. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors: J C Rodríguez; M Ruiz; M López; G Royo
Journal: Int J Antimicrob Agents Date: 2002-12 Impact factor: 5.283

Review 2. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors: C S Lewin; I Morrissey; J T Smith
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-04 Impact factor: 3.267

Review 3. Genetic systems for mycobacteria.

Authors: W R Jacobs; G V Kalpana; J D Cirillo; L Pascopella; S B Snapper; R A Udani; W Jones; R G Barletta; B R Bloom
Journal: Methods Enzymol Date: 1991 Impact factor: 1.600

4. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors: Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal: Antimicrob Agents Chemother Date: 2000-09 Impact factor: 5.191

5. Bactericidal mechanisms of ofloxacin.

Authors: C S Lewin; J T Smith
Journal: J Antimicrob Chemother Date: 1988-09 Impact factor: 5.790

6. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

Authors: Tetsuyuki Yoshimatsu; Eric Nuermberger; Sandeep Tyagi; Richard Chaisson; William Bishai; Jacques Grosset
Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191

7. Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol.

Authors: Muhammad Malik; Tao Lu; Xilin Zhao; Anubha Singh; Christopher M Hattan; John Domagala; Robert Kerns; Karl Drlica
Journal: Antimicrob Agents Chemother Date: 2005-05 Impact factor: 5.191

Review 8. Bacterial resistance to quinolones: mechanisms and clinical importance.

Authors: J S Wolfson; D C Hooper
Journal: Rev Infect Dis Date: 1989 Jul-Aug

9. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

Authors: Enrique J Alvirez-Freites; Janna L Carter; Michael H Cynamon
Journal: Antimicrob Agents Chemother Date: 2002-04 Impact factor: 5.191

10. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.

Authors: Tao Lu; Karl Drlica
Journal: J Antimicrob Chemother Date: 2003-11-12 Impact factor: 5.790

17 in total

1. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Authors: Zahoor Ahmad; Austin Minkowski; Charles A Peloquin; Kathy N Williams; Khisimuzi E Mdluli; Jacques H Grosset; Eric L Nuermberger
Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191

Review 2. Quinolone-mediated bacterial death.

Authors: Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal: Antimicrob Agents Chemother Date: 2007-08-27 Impact factor: 5.191

10. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors: Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal: Am J Respir Crit Care Med Date: 2013-07-01 Impact factor: 21.405

Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

1. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Review 2. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Review 3. Genetic systems for mycobacteria.

4. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

5. Bactericidal mechanisms of ofloxacin.

6. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

7. Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol.

Review 8. Bacterial resistance to quinolones: mechanisms and clinical importance.

9. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

10. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.

1. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Review 2. Quinolone-mediated bacterial death.

3. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.

4. Effect of anaerobic growth on quinolone lethality with Escherichia coli.

5. Involvement of Holliday junction resolvase in fluoroquinolone-mediated killing of Mycobacterium smegmatis.

6. Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.

Review 7. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

8. In vitro model of mycobacterial growth arrest using nitric oxide with limited air.

9. Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.

10. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.